Liniger C, Pometta D, Burger A G
J Endocrinol. 1987 Jan;112(1):171-5. doi: 10.1677/joe.0.1120171.
SR-202 is a non-iodinated potential lipid-altering agent. When administered (100 mg) three times per day for 3 days to six euthyroid subjects it was associated with a 30 +/- 3% (mean +/- S.E.M.) fall in 3,3',5-triiodothyronine (T3) (P less than 0.001), a reciprocal 104 +/- 14% rise in 3,3',5'-tri-iodothyronine (reverse T3, rT3) (P less than 0.01), and a 37 +/- 7% rise in thyroxine (T4) (P less than 0.001). Basal and TRH-stimulated TSH did not change. These results suggested that SR-202 was acting as an inhibitor of the peripheral monodeiodination of T4 to T3. During a second study the same subjects received the same dose of SR-202 for a further 3 days following 15 days of progressive substitutive treatment with L-T4, which they continued to take at 200 micrograms/day until the end of the study. Despite higher levels of thyroid hormones in the substituted subjects, similar results were observed, serum T3 falling by 40 +/- 2% (P less than 0.001), serum rT3 and T4 rising by 168 +/- 24% (P less than 0.01) and 37 +/- 9% (P less than 0.01) respectively. These changes provide compelling evidence that SR-202 is an inhibitor of the peripheral conversion of T4 to T3 that acts on thyroid hormone metabolism without provoking a counter-regulatory pituitary response. It might prove to be a useful tool for the clinical investigation of thyroid function.
SR - 202是一种非碘化的潜在脂质改变剂。给6名甲状腺功能正常的受试者每天服用3次(每次100毫克),持续3天,结果显示血清三碘甲状腺原氨酸(T3)下降了30±3%(平均值±标准误)(P<0.001),反三碘甲状腺原氨酸(rT3)相应升高了104±14%(P<0.01),甲状腺素(T4)升高了37±7%(P<0.001)。基础促甲状腺激素(TSH)以及促甲状腺激素释放激素(TRH)刺激后的TSH均未发生变化。这些结果表明,SR - 202可作为T4外周单脱碘转化为T3的抑制剂。在第二项研究中,同一批受试者在接受左旋甲状腺素(L - T4)进行15天的逐步替代治疗后,继续每天服用200微克L - T4直至研究结束,在此之后再给予相同剂量的SR - 202,持续3天。尽管替代治疗后的受试者甲状腺激素水平较高,但仍观察到类似结果,血清T3下降了40±2%(P<0.001),血清rT3和T4分别升高了168±24%(P<0.01)和37±9%(P<0.01)。这些变化提供了有力证据,表明SR - 202是T4外周转化为T3的抑制剂,作用于甲状腺激素代谢,且不会引发垂体的反调节反应。它可能被证明是甲状腺功能临床研究的有用工具。